| Literature DB >> 33150981 |
Coralie Assailly1, Clarisse Bridot2, Amélie Saumonneau3, Paul Lottin4, Benoit Roubinet5, Eva-Maria Krammer2, Francesca François4, Federica Vena5, Ludovic Landemarre5, Dimitri Alvarez Dorta1, David Deniaud1, Cyrille Grandjean3, Charles Tellier3, Sagrario Pascual4, Véronique Montembault4, Laurent Fontaine4, Franck Daligault3, Julie Bouckaert2, Sébastien G Gouin1.
Abstract
Bacterial sialidases (SA) are validated drug targets expressed by common human pathogens such as Streptococcus pneumoniae, Vibrio cholerae, or Clostridium perfringens. Noncovalent inhibitors of bacterial SA capable of reaching the submicromolar level are rarely reported. In this work, multi- and polyvalent compounds are developed, based on the transition-state analogue 2-deoxy-2,3-didehydro-N-acetylneuraminic (DANA). Poly-DANA inhibits the catalytic activity of SA from S. pneumoniae (NanA) and the symbiotic microorganism B. thetaiotaomicron (BtSA) at the picomolar and low nanomolar levels (expressed in moles of molecules and of DANA, respectively). Each DANA grafted to the polymer surpasses the inhibitory potential of the monovalent analogue by more than four orders of magnitude, which represents the highest multivalent effect reported so far for an enzyme inhibition. The synergistic interaction is shown to operate exclusively in the catalytic domain, and not in the flanked carbohydrate-binding module (CBM). These results offer interesting perspectives for the multivalent inhibition of other SA families lacking a CBM, such as viral, parasitic, or human SA.Entities:
Keywords: enzymes; inhibitors; multivalency; sialidases
Year: 2021 PMID: 33150981 DOI: 10.1002/chem.202004672
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236